BioCentury
ARTICLE | Clinical News

Omadacycline: Ph III OPTIC data

April 7, 2017 7:18 PM UTC

Top-line data from 774 patients with CABP in the ITT population of the double-blind, international Phase III OPTIC trial showed that once-daily IV-to-oral omadacycline for 7-14 days met the FDA-define...

BCIQ Company Profiles

Paratek Pharmaceuticals Inc.

BCIQ Target Profiles

Ribosomal 30S subunit